Postmarketing surveillance of enalapril. II: Investigation of the potential role of enalapril in deaths with renal failure.
暂无分享,去创建一个
C. Dollery | W. Inman | C. Speirs | N. Rawson | L. Wilton
[1] W. Inman,et al. Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring. , 1988, BMJ.
[2] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[3] D. Brown,et al. Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice. , 1987, The Journal of the Royal College of General Practitioners.
[4] Renal syndromes associated with non-steroidal anti-inflammatory drugs , 1984 .
[5] Y. Sugiyama,et al. Binding of glutathione by rat liver cytosol. , 1984, Pharmacology.
[6] E. Freis,et al. Low-dose captopril for the treatment of mild to moderate hypertension. , 1983, Hypertension.
[7] L. Horowitz,et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. , 1983, Journal of the American College of Cardiology.
[8] M. Schreiber,et al. Renal failure associated with captopril. , 1983, JAMA.
[9] W. Blythe. Captopril and renal autoregulation. , 1983, The New England journal of medicine.
[10] N. Hollenberg. Renal response to angiotensin-converting enzyme inhibition. , 1982, The American journal of cardiology.
[11] M. Vallotton,et al. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. , 1982, Annals of internal medicine.
[12] E Scowen,et al. Committee on Safety of Medicines. , 1978, British journal of anaesthesia.
[13] K. Lynn,et al. Spironolactone-associated aggravation of renal functional impairment. , 1976, The New Zealand medical journal.